The FDA can’t get its story straight about reducing tobacco-related dangers

FDA Commissioner Robert Califf faced tough questions from the House Oversight Committee, addressing FDA's actions on various products. The session highlighted delays in recognizing tobacco harm reduction and the FDA's push for more user fees on tobacco. Califf hesitated to fully endorse e-cigarettes for harm reduction, despite acknowledging their reduced toxicity. The FDA's inconsistent stance on risk continuum and authorization of few e-cigarette products are concerning. Repetitive rejection of vapor product applications raises questions about prioritizing youth over adult smokers. Congressional intervention may be needed to align FDA actions with reducing tobacco-related harm effectively.